NO306979B1 - Fremgangsmåte for fremstilling av et farmasoeytisk preparat for behandling av kardial så vel som vaskulaer hypertrofi og hyperplasi - Google Patents

Fremgangsmåte for fremstilling av et farmasoeytisk preparat for behandling av kardial så vel som vaskulaer hypertrofi og hyperplasi Download PDF

Info

Publication number: NO306979B1
Authority: NO; Norway
Prior art keywords: alkyl; aryl; carboxylic acid; carbethoxy; atoms
Prior art date: 1989-08-11

Application number

NO903532A

Other languages

English (en)

Norwegian (no)

Other versions

NO903532D0 (no

NO903532L (no

Inventor

Wolfgang Linz

Bernward Schoelkens

Wolfgang Scholz

Gabriele Wiemer

Hansjoerg Urbach

Rainer Henning

Volker Teetz

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-11

Filing date

1990-08-10

Publication date

2000-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6386970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306979(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-08-10 Application filed by Hoechst Ag filed Critical Hoechst Ag

1990-08-10 Publication of NO903532D0 publication Critical patent/NO903532D0/no

1991-02-12 Publication of NO903532L publication Critical patent/NO903532L/no

2000-01-24 Publication of NO306979B1 publication Critical patent/NO306979B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 18
206010072810 Vascular wall hypertrophy Diseases 0.000 title claims abstract description 10
230000000747 cardiac effect Effects 0.000 title claims abstract description 10
206010020718 hyperplasia Diseases 0.000 title claims abstract description 8
206010007572 Cardiac hypertrophy Diseases 0.000 title claims description 11
208000006029 Cardiomegaly Diseases 0.000 title claims description 11
238000002360 preparation method Methods 0.000 title claims description 5
239000008194 pharmaceutical composition Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 18
239000005541 ACE inhibitor Substances 0.000 claims abstract description 12
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
239000001257 hydrogen Substances 0.000 claims abstract description 9
125000003118 aryl group Chemical group 0.000 claims description 31
125000004432 carbon atom Chemical group C* 0.000 claims description 18
DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 claims description 17
-1 nitro, amino Chemical group 0.000 claims description 15
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
125000006413 ring segment Chemical group 0.000 claims description 14
229910052717 sulfur Inorganic materials 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 9
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 6
125000003003 spiro group Chemical group 0.000 claims description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000004430 oxygen atom Chemical group O* 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
ADKDJHASTPQGEO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrole Chemical compound C1CNC2CCCC21 ADKDJHASTPQGEO-UHFFFAOYSA-N 0.000 claims description 4
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 claims description 4
PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 claims description 4
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 4
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 4
125000003342 alkenyl group Chemical group 0.000 claims description 4
235000008206 alpha-amino acids Nutrition 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
SBUWIPJHZAJVSM-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydrocyclohepta[b]pyrrole Chemical compound C1CCCCC2NCCC21 SBUWIPJHZAJVSM-UHFFFAOYSA-N 0.000 claims description 3
ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 claims description 3
MFOUWLGLIHXCOZ-UHFFFAOYSA-N 2,3,3a,4,5,7a-hexahydro-1h-indole Chemical compound C1CC=CC2NCCC21 MFOUWLGLIHXCOZ-UHFFFAOYSA-N 0.000 claims description 3
WSSDGZWSPMAECX-UHFFFAOYSA-N 2-azabicyclo[3.1.0]hexane Chemical compound C1CNC2CC21 WSSDGZWSPMAECX-UHFFFAOYSA-N 0.000 claims description 3
NINJAJLCZUYDGV-UHFFFAOYSA-N 2-azaspiro[4.4]nonane Chemical compound C1CCCC21CNCC2 NINJAJLCZUYDGV-UHFFFAOYSA-N 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 3
150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 3
125000001041 indolyl group Chemical group 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
125000000304 alkynyl group Chemical group 0.000 claims description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
125000002619 bicyclic group Chemical group 0.000 claims description 2
239000012050 conventional carrier Substances 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
238000001035 drying Methods 0.000 claims description 2
238000001914 filtration Methods 0.000 claims description 2
238000000227 grinding Methods 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
FLLUHHKAVNMUKU-OFQXOLIOSA-N (3s,4as)-2-[(2s)-2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl]-3,4,4a,5-tetrahydro-1h-isoquinoline-3-carboxylic acid Chemical compound N([C@@H](C)C(=O)N1[C@@H](C[C@@H]2CC=CC=C2C1)C(O)=O)C(C(=O)OCC)CCC1=CC=CC=C1 FLLUHHKAVNMUKU-OFQXOLIOSA-N 0.000 claims 1
LALGNVUJKVMZMO-OCVXTVMPSA-N (3s,4as,8as)-2-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(O)=O)CC1=CC=CC=C1 LALGNVUJKVMZMO-OCVXTVMPSA-N 0.000 claims 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
125000004494 ethyl ester group Chemical group 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 4
239000003795 chemical substances by application Substances 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
102000005862 Angiotensin II Human genes 0.000 description 6
101800000733 Angiotensin-2 Proteins 0.000 description 6
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 6
229950006323 angiotensin ii Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
206010020772 Hypertension Diseases 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
CQYBNXGHMBNGCG-FXQIFTODSA-N (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-1-ium-2-carboxylate Chemical compound C1CCC[C@@H]2[NH2+][C@H](C(=O)[O-])C[C@@H]21 CQYBNXGHMBNGCG-FXQIFTODSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
230000003276 anti-hypertensive effect Effects 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
238000007327 hydrogenolysis reaction Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
229960003401 ramipril Drugs 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000126 substance Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
VXFJYXUZANRPDJ-MQBSTWLZSA-N (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-MQBSTWLZSA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
XRKXJJYSKUIIEN-UHFFFAOYSA-N 2-[cyclopentyl-[3-(2,2-dimethylpropanoylsulfanyl)-2-methylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)C(=O)SCC(C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-UHFFFAOYSA-N 0.000 description 1
SFCOKGCNIPSUQF-UHFFFAOYSA-N 2-azaspiro[4.5]decane Chemical compound C1NCCC21CCCCC2 SFCOKGCNIPSUQF-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
229950007884 alacepril Drugs 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001371 alpha-amino acids Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
108700025906 fos Genes Proteins 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
150000002668 lysine derivatives Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
150000002763 monocarboxylic acids Chemical class 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
BSIZUMJRKYHEBR-QGZVFWFLSA-N n-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002674 ointment Substances 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
229960002769 zofenopril Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)
Crucibles And Fluidized-Bed Furnaces (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preliminary Treatment Of Fibers (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Element Separation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

NO903532A 1989-08-11 1990-08-10 Fremgangsmåte for fremstilling av et farmasoeytisk preparat for behandling av kardial så vel som vaskulaer hypertrofi og hyperplasi NO306979B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3926606A DE3926606A1 (de)	1989-08-11	1989-08-11	Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (3)

Publication Number	Publication Date
NO903532D0 NO903532D0 (no)	1990-08-10
NO903532L NO903532L (no)	1991-02-12
NO306979B1 true NO306979B1 (no)	2000-01-24

Family

ID=6386970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO903532A NO306979B1 (no)	1989-08-11	1990-08-10	Fremgangsmåte for fremstilling av et farmasoeytisk preparat for behandling av kardial så vel som vaskulaer hypertrofi og hyperplasi

Country Status (22)

Country	Link
US (1)	US5231083A (fi)
EP (1)	EP0417473B1 (fi)
JP (1)	JP3452199B2 (fi)
KR (1)	KR0185969B1 (fi)
AT (1)	ATE94409T1 (fi)
AU (1)	AU631914B2 (fi)
CA (1)	CA2023089C (fi)
CS (1)	CS277644B6 (fi)
DD (1)	DD297063A5 (fi)
DE (2)	DE3926606A1 (fi)
DK (1)	DK0417473T3 (fi)
ES (1)	ES2059931T3 (fi)
FI (1)	FI903936A7 (fi)
HU (1)	HU205008B (fi)
IE (1)	IE64604B1 (fi)
IL (1)	IL95327A (fi)
NO (1)	NO306979B1 (fi)
NZ (1)	NZ234836A (fi)
PH (1)	PH30831A (fi)
PL (1)	PL286442A1 (fi)
PT (1)	PT94957B (fi)
ZA (1)	ZA906327B (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0682947B1 (en)	1994-05-19	1997-09-10	Mitsubishi Chemical Corporation	Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
SG68529A1 (en) *	1995-05-25	1999-11-16	Univ Singapore	The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
DK1216038T3 (da) *	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2006052968A2 (en) *	2004-11-05	2006-05-18	King Pharmaceuticals Research & Development, Inc.	Stabilized ramipril compositions and methods of making
WO2012071369A2 (en)	2010-11-24	2012-05-31	The Trustees Of Columbia University In The City Of New York	A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9333202B2 (en)	2012-05-01	2016-05-10	The Trustees Of Columbia University In The City Of New York	Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
WO2014152018A1 (en) *	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydrocyclopentapyrroles, their preparation and use
WO2014151936A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydropyrrolopyrroles, their preparation and use
ES2705247T3 (es)	2013-03-14	2019-03-22	Univ Columbia	4-fenilpiperidinas, su preparación y uso
WO2014151959A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	N-alkyl-2-phenoxyethanamines, their preparation and use
CN111393434B (zh)	2014-04-30	2022-11-04	哥伦比亚大学董事会	取代的4-苯基哌啶及其制备和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL58849A (en) *	1978-12-11	1983-03-31	Merck & Co Inc	Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4311705A (en) *	1980-10-06	1982-01-19	E. R. Squibb & Sons, Inc.	Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4337201A (en) *	1980-12-04	1982-06-29	E. R. Squibb & Sons, Inc.	Phosphinylalkanoyl substituted prolines
US4381297A (en) *	1981-05-04	1983-04-26	E. R. Squibb & Sons, Inc.	Substituted carbonyl phosphinyl-alkanoyl compounds
US4602002A (en) *	1983-02-07	1986-07-22	Merck & Co., Inc.	N-carboxymethyl substituted lysyl and α-(ε-aminoalkyl) glycyl amino acid antihypertensive agents
US4548941A (en) *	1984-07-30	1985-10-22	Merck & Co., Inc.	1,5-Methano-1H-4-benzazonine dicarboxylates, process for preparing and use as calcium blockers
US4587253A (en) *	1984-07-30	1986-05-06	Merck & Co., Inc.	Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4599341A (en) *	1984-10-01	1986-07-08	Merck & Co., Inc.	Substituted and bridged pyridines useful as calcium channel blockers
US4656188A (en) *	1985-10-09	1987-04-07	Merck & Co., Inc.	Ace inhibitors in macular degeneration
DE3705220A1 (de) *	1987-02-19	1988-09-01	Boehringer Ingelheim Kg	Mittel zur behandlung von coronarerkrankungen oder organischem hirnsyndrom
ZA896851B (en) *	1988-09-14	1990-06-27	Hoffmann La Roche	Use of ace-inhibitors

1989
- 1989-08-11 DE DE3926606A patent/DE3926606A1/de not_active Withdrawn
1990
- 1990-08-08 AT AT90115230T patent/ATE94409T1/de not_active IP Right Cessation
- 1990-08-08 DE DE90115230T patent/DE59002721D1/de not_active Expired - Lifetime
- 1990-08-08 ES ES90115230T patent/ES2059931T3/es not_active Expired - Lifetime
- 1990-08-08 EP EP90115230A patent/EP0417473B1/de not_active Expired - Lifetime
- 1990-08-08 DK DK90115230.6T patent/DK0417473T3/da active
- 1990-08-09 IL IL9532790A patent/IL95327A/en unknown
- 1990-08-09 NZ NZ234836A patent/NZ234836A/en unknown
- 1990-08-09 FI FI903936A patent/FI903936A7/fi not_active Application Discontinuation
- 1990-08-09 PH PH41000A patent/PH30831A/en unknown
- 1990-08-09 DD DD90343366A patent/DD297063A5/de unknown
- 1990-08-09 PT PT94957A patent/PT94957B/pt not_active IP Right Cessation
- 1990-08-09 US US07/564,618 patent/US5231083A/en not_active Expired - Lifetime
- 1990-08-10 ZA ZA906327A patent/ZA906327B/xx unknown
- 1990-08-10 KR KR1019900012267A patent/KR0185969B1/ko not_active Expired - Lifetime
- 1990-08-10 HU HU904966A patent/HU205008B/hu unknown
- 1990-08-10 NO NO903532A patent/NO306979B1/no not_active IP Right Cessation
- 1990-08-10 AU AU60920/90A patent/AU631914B2/en not_active Expired
- 1990-08-10 CA CA002023089A patent/CA2023089C/en not_active Expired - Lifetime
- 1990-08-10 PL PL28644290A patent/PL286442A1/xx unknown
- 1990-08-10 IE IE291090A patent/IE64604B1/en not_active IP Right Cessation
- 1990-08-10 CS CS903958A patent/CS277644B6/cs not_active IP Right Cessation
- 1990-08-10 JP JP21056490A patent/JP3452199B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PT94957B (pt)	1997-05-28
IL95327A (en)	1995-10-31
NO903532D0 (no)	1990-08-10
FI903936A7 (fi)	1991-02-12
ES2059931T3 (es)	1994-11-16
US5231083A (en)	1993-07-27
NO903532L (no)	1991-02-12
IE64604B1 (en)	1995-08-23
ATE94409T1 (de)	1993-10-15
JP3452199B2 (ja)	2003-09-29
DE59002721D1 (de)	1993-10-21
HUT54504A (en)	1991-03-28
FI903936A0 (fi)	1990-08-09
IE902910A1 (en)	1991-02-27
KR910004189A (ko)	1991-03-28
ZA906327B (en)	1991-05-29
NZ234836A (en)	1997-05-26
EP0417473B1 (de)	1993-09-15
JPH0383957A (ja)	1991-04-09
IL95327A0 (en)	1991-06-30
DD297063A5 (de)	1992-01-02
CA2023089A1 (en)	1991-02-12
DK0417473T3 (da)	1993-12-13
PT94957A (pt)	1991-05-22
PL286442A1 (en)	1992-03-09
EP0417473A1 (de)	1991-03-20
HU205008B (en)	1992-03-30
HU904966D0 (en)	1991-01-28
AU6092090A (en)	1991-02-14
PH30831A (en)	1997-10-17
CA2023089C (en)	2003-01-14
AU631914B2 (en)	1992-12-10
KR0185969B1 (ko)	1999-05-01
CS277644B6 (en)	1993-03-17
CS395890A3 (en)	1992-08-12
DE3926606A1 (de)	1991-02-14

Publication	Publication Date	Title
US5256687A (en)	1993-10-26	Pharmaceutical composition for the treatment of high blood pressure
KR930008094B1 (ko)	1993-08-25	안기오텐신 전환효소 억제제의 제조방법
NO306979B1 (no)	2000-01-24	Fremgangsmåte for fremstilling av et farmasoeytisk preparat for behandling av kardial så vel som vaskulaer hypertrofi og hyperplasi
US5231080A (en)	1993-07-27	Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5403856A (en)	1995-04-04	Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors
DK172221B1 (da)	1998-01-12	Anvendelse af ACE-inhibitorer eller deres fysiologisk acceptable salte til fremstilling af lægemidler med nootrop virkning
US5684016A (en)	1997-11-04	Method of treating cardiac insufficiency
US5231084A (en)	1993-07-27	Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
NO311070B1 (no)	2001-10-08	Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende trandolapril og verapamil
JPH01246222A (ja)	1989-10-02	向精神作用を有する化合物およびそれらを含有する薬剤
NO863583L (no)	1987-03-10	Farmasoeytisk tilberedning til behandling av hoeyt blodtrykk
JPH01128997A (ja)	1989-05-22	アミノ酸エステル及びその製造方法
KR900003321B1 (ko)	1990-05-14	인식보조작용이 있는 화합물, 이를 함유하는 제제 및 인식 기능 장애를 치료하고 예방하는데 있어서 이의 용도
HK1006148B (en)	1999-02-12	Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria

Legal Events

Date	Code	Title	Description
2010-08-16	MK1K	Patent expired